Shopping Cart
- Remove All
Your shopping cart is currently empty
Zotizalkib (TPX-0131) is an orally active and selective ALK inhibitor with antitumor activity for the study of non-small cell lung cancer.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $129 | In Stock | |
| 5 mg | $319 | In Stock | |
| 10 mg | $513 | In Stock | |
| 25 mg | $987 | In Stock | |
| 50 mg | $1,550 | In Stock | |
| 100 mg | $2,180 | In Stock | |
| 200 mg | $2,950 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $352 | In Stock |
| Description | Zotizalkib (TPX-0131) is an orally active and selective ALK inhibitor with antitumor activity for the study of non-small cell lung cancer. |
| Targets&IC50 | ALK (WT):1.4 nM |
| In vitro | Zotizalkib effectively inhibited wild-type ALK with an IC50 value of 1.4 nM, and also showed inhibitory activity against 26 ALK resistance mutations. Zotizalkib also showed effective inhibition of ALK autophosphorylation in Ba/F3 cells expressing EML4-ALK G1202R, EML4-ALK G1202R/L1196M or EML4-ALK G1202R/L1198F mutations, with an IC50 value of about 3-10 nM. [1] |
| In vivo | Zotizalkib was administered orally at a dose of 2-10 mg/kg twice daily for 2 weeks, with the 2 mg/kg, 5 mg/kg, and 10 mg/kg doses exhibiting 64%, 120%, and 200% dose-dependent tumor growth inhibition, respectively. [1] |
| Synonyms | TPX-0131, TPX0131 |
| Molecular Weight | 447.41 |
| Formula | C21H20F3N5O3 |
| Cas No. | 2648641-36-3 |
| Smiles | C(F)(F)[C@H]1N2C=3C(=CN4C(N3)=C(C=N4)C(=O)NC(C)(C)COC=5C(C2)=CC(F)=CC5)OC1 |
| Relative Density. | 1.56 g/cm3 (Predicted) |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 20 mg/mL (44.7 mM), Sonication is recommended. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.